U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K.

Sir Keir Starmer and his health secretary have been lauding the potential of the new generation of weight-loss drugs. Given as regular injections, the treatments – Wegovy and Mounjaro – mimic a hormone that makes people less hungry.

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.

The future of the weight loss market might not revolve around GLP-1 drugs.

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and Zepbound.

Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how much is this going to set me back? Lucky for you, we’ve done our homework.

As for why it’s not approved for weight loss in the UK, Dr Kayat added: “It works by helping to regulate your appetite and reduce cravings and hunger. But in the UK, it’s only supposed to be used for type 2 diabetes, and that’s in order to try and protect the resources for the type 2 diabetics.”

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound,